Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

amicus therapeutics pty ltd - migalastat hydrochloride, quantity: 150 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; indigo carmine; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; gelatin; sodium lauryl sulfate - galafold is indicated for long-term treatment of adult and adolescent patients 12 years and older with a confirmed diagnosis of fabry disease (alpha-galactosidase a deficiency) and who have an amenable mutation (see the table in section 5.1 pharmacodynamic properties, mechanism of action).

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

glaxosmithkline llc - ezogabine (unii: 12g01i6bbu) (ezogabine - unii:12g01i6bbu) - ezogabine 50 mg - potiga® is indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity [see warnings and precautions (5.1)] . none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. potiga should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in animal studies, doses associated with maternal plasma exposures (auc) to ezogabine and its major circulating metabolite, n-acetyl metabolite of ezogabine (namr), similar to or below those expected in humans at the maximum recommended human dose (mrhd) of 1,200 mg per day produced developmental toxicity when administered to pregnant rats and rabbits. the maximum doses evaluated were limited by maternal toxicity (acute neurotoxicity). treatment of pregnant rats with ezogabine (oral doses

Izraēla - angļu - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Izraēla - angļu - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Izraēla - angļu - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: dimeticone 350; purified talc; hyprolose; purified water; indigo carmine; hypromellose; carrageenan; acacia; potassium chloride; titanium dioxide; tartaric acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - valganciclovir, quantity: 5 g - solution, powder for - excipient ingredients: mannitol; fumaric acid; sodium benzoate; saccharin sodium; povidone; flavour - valcyte is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids). valcyte is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 126.83 mg (equivalent: dabigatran etexilate, qty 110 mg) - capsule, hard - excipient ingredients: hyprolose; hypromellose; tartaric acid; dimeticone 350; potassium chloride; acacia; purified talc; titanium dioxide; carrageenan; indigo carmine; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dabigatran etexilate mesilate, quantity: 86.48 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: hypromellose; titanium dioxide; potassium chloride; purified talc; carrageenan; tartaric acid; hyprolose; purified water; acacia; dimeticone 350; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). (see section 4.2 dose and method of administration for details of treatment duration). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Panama - angļu - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

genfar, s.a. - valganciclovir (hcl) - valganciclovir (hcl)....450,00 mg